Opicapone is not approved

Opicapone is a novel once-daily oral selective catechol-O-methyltransferase (COMT) inhibitor used as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease. Parkinson's disease is a chronic, progressive and debilitating neurodegenerative disease. Opicapone has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), but it has not yet been approved for marketing in China.

Opicapone is supported by clinical data from twoPhase III studies (BIPARK-1 and BIPARK-2), in which more than 1,000 Parkinson's disease patients received Opicapone. BIPARK-1 is a Phase III randomized double-blind placebo and active-controlled study of opicapone as an adjunct to levodopa therapy, and BIPARK-2 is a Phase III randomized double-blind placebo-controlled study of opicapone as an adjunct to levodopa therapy. Data from both trials showed that opicapone 50 mg significantly reduced "off" time from baseline to weeks 14-15 compared with placebo. "On" time without bothersome dyskinesia also increased from baseline to weeks 14-15 compared with placebo.

Since the original drug of Opicapone has not yet been launched in China, it is not included in the scope of medical insurance. The European version of Opicapone’s original drug specifications listed overseasThe price per box of 50mg*90 capsules is around RMB 6,000 (the price may fluctuate due to the exchange rate). There is currently no generic version of Opicapone on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.